Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:36 UTC |
---|
HMDB ID | HMDB0014388 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Ranolazine |
---|
Description | Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia ]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia. |
---|
Structure | COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1 InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29) |
---|
Synonyms | Value | Source |
---|
Ranexa | Kegg | (-)-Ranolazine | HMDB | Ranolazine 2HCL | HMDB | HCL, Ranolazine | MeSH, HMDB | Hydrochloride, ranolazine | MeSH, HMDB | Ranolazine hydrochloride | MeSH, HMDB | Renolazine | MeSH, HMDB | Dihydrochloride, ranolazine | MeSH, HMDB | Ranolazine dihydrochloride | MeSH, HMDB | Ranolazine HCL | MeSH, HMDB | N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide | MeSH, HMDB | Ranolazine | MeSH |
|
---|
Chemical Formula | C24H33N3O4 |
---|
Average Molecular Weight | 427.5365 |
---|
Monoisotopic Molecular Weight | 427.247106559 |
---|
IUPAC Name | N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide |
---|
Traditional Name | ranolazine |
---|
CAS Registry Number | 142387-99-3 |
---|
SMILES | COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1 |
---|
InChI Identifier | InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29) |
---|
InChI Key | XKLMZUWKNUAPSZ-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Phenol ethers |
---|
Sub Class | Anisoles |
---|
Direct Parent | Anisoles |
---|
Alternative Parents | |
---|
Substituents | - Phenoxy compound
- Anisole
- M-xylene
- Xylene
- Methoxybenzene
- Alkyl aryl ether
- N-alkylpiperazine
- Monocyclic benzene moiety
- 1,4-diazinane
- Piperazine
- 1,2-aminoalcohol
- Secondary alcohol
- Tertiary amine
- Tertiary aliphatic amine
- Carboximidic acid
- Carboximidic acid derivative
- Azacycle
- Ether
- Organoheterocyclic compound
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Alcohol
- Organic nitrogen compound
- Organic oxygen compound
- Amine
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.11 g/L | Not Available | LogP | 1.6 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Ranolazine,1TMS,isomer #1 | COC1=CC=CC=C1OCC(CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1)O[Si](C)(C)C | 3469.8 | Semi standard non polar | 33892256 | Ranolazine,1TMS,isomer #2 | COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)N(C2=C(C)C=CC=C2C)[Si](C)(C)C)CC1 | 3294.0 | Semi standard non polar | 33892256 | Ranolazine,2TMS,isomer #1 | COC1=CC=CC=C1OCC(CN1CCN(CC(=O)N(C2=C(C)C=CC=C2C)[Si](C)(C)C)CC1)O[Si](C)(C)C | 3289.2 | Semi standard non polar | 33892256 | Ranolazine,2TMS,isomer #1 | COC1=CC=CC=C1OCC(CN1CCN(CC(=O)N(C2=C(C)C=CC=C2C)[Si](C)(C)C)CC1)O[Si](C)(C)C | 3148.9 | Standard non polar | 33892256 | Ranolazine,2TMS,isomer #1 | COC1=CC=CC=C1OCC(CN1CCN(CC(=O)N(C2=C(C)C=CC=C2C)[Si](C)(C)C)CC1)O[Si](C)(C)C | 4361.4 | Standard polar | 33892256 | Ranolazine,1TBDMS,isomer #1 | COC1=CC=CC=C1OCC(CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1)O[Si](C)(C)C(C)(C)C | 3691.9 | Semi standard non polar | 33892256 | Ranolazine,1TBDMS,isomer #2 | COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)N(C2=C(C)C=CC=C2C)[Si](C)(C)C(C)(C)C)CC1 | 3500.2 | Semi standard non polar | 33892256 | Ranolazine,2TBDMS,isomer #1 | COC1=CC=CC=C1OCC(CN1CCN(CC(=O)N(C2=C(C)C=CC=C2C)[Si](C)(C)C(C)(C)C)CC1)O[Si](C)(C)C(C)(C)C | 3670.5 | Semi standard non polar | 33892256 | Ranolazine,2TBDMS,isomer #1 | COC1=CC=CC=C1OCC(CN1CCN(CC(=O)N(C2=C(C)C=CC=C2C)[Si](C)(C)C(C)(C)C)CC1)O[Si](C)(C)C(C)(C)C | 3520.6 | Standard non polar | 33892256 | Ranolazine,2TBDMS,isomer #1 | COC1=CC=CC=C1OCC(CN1CCN(CC(=O)N(C2=C(C)C=CC=C2C)[Si](C)(C)C(C)(C)C)CC1)O[Si](C)(C)C(C)(C)C | 4426.0 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Ranolazine GC-MS (Non-derivatized) - 70eV, Positive | splash10-00di-0960000000-fec44fb0c944059ff910 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ranolazine GC-MS (1 TMS) - 70eV, Positive | splash10-00di-3955300000-205c596ad90919eac144 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ranolazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ranolazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ranolazine GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ranolazine GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Ranolazine GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Ranolazine LC-ESI-qTof , Positive-QTOF | splash10-0udi-0010900000-41c6c10d624710416f8e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ranolazine , positive-QTOF | splash10-0udi-0010900000-41c6c10d624710416f8e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ranolazine , positive-QTOF | splash10-004i-1321900000-58e490b47155b2267ecc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ranolazine , positive-QTOF | splash10-004i-1320900000-9a6cdfcd606e98d38452 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ranolazine , positive-QTOF | splash10-004i-0320900000-ab04122e7d0d6e7c3690 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ranolazine , positive-QTOF | splash10-004i-5951300000-885e790d3cd4d8746c02 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ranolazine 35V, Negative-QTOF | splash10-001i-0190000000-6319b1c775f27bd8c8ce | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ranolazine 35V, Positive-QTOF | splash10-004i-1240900000-d3069ce6b5d688a4783b | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 10V, Positive-QTOF | splash10-004i-0590200000-2f0530ce2db07c01dbb4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 20V, Positive-QTOF | splash10-0200-1950000000-1147b10f00f99b50c828 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 40V, Positive-QTOF | splash10-03di-1900000000-74fa7798b15582c216e5 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 10V, Negative-QTOF | splash10-00b9-0710900000-09291e56b9aef129f871 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 20V, Negative-QTOF | splash10-05fr-1900000000-9ca0fb6599e918e85e84 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 40V, Negative-QTOF | splash10-0ab9-3900000000-b5af33130090f877b66a | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 10V, Negative-QTOF | splash10-00b9-0884900000-f03ddc85c7181df22475 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 20V, Negative-QTOF | splash10-001r-0952100000-7af7dd6f35711dc59695 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 40V, Negative-QTOF | splash10-059g-1941200000-b2780a3ccbe1bf73d1a1 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 10V, Positive-QTOF | splash10-004i-0005900000-1f0abdb439637a86f826 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 20V, Positive-QTOF | splash10-0fk9-0539100000-5f686a8e215943300bbf | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ranolazine 40V, Positive-QTOF | splash10-06xy-2920100000-25b7bdd69da447f08293 | 2021-09-24 | Wishart Lab | View Spectrum |
|
---|
General References | - Hale SL, Kloner RA: Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther. 2006 Dec;11(4):249-55. [PubMed:17220471 ]
- Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):309-16. [PubMed:14734593 ]
- Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L: Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006 Aug 1;48(3):566-75. Epub 2006 Jun 15. [PubMed:16875985 ]
- Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS: Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006 Dec;41(6):1031-8. Epub 2006 Oct 5. [PubMed:17027025 ]
- Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007 Apr 25;297(16):1775-83. [PubMed:17456819 ]
|
---|